RickyKHsuMD

PubMed

• 78 citations
  Weight gain before and after switch from TDF to TAF in a U.S. cohort study
  Patrick W. G. Mallon, Laurence Brunet, Ricky Hsu, Jennifer S Fusco, Karam Mounzer
  Journal of the International AIDS Society. 2021-04-01
• 914 citations
  The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
  Florencia Pereyra, Xiaoming Jia, Paul J. McLaren, Amalio Telenti, de Bakker Pi
  Science. 2010-12-10
• 77 citations
  Psychiatric Symptoms in Patients Receiving Dolutegravir.
  Anna Fettiplace, C. Stainsby, Alan Winston, Naomi Givens, Sarah Puccini
  Journal of Acquired Immune Deficiency Syndromes. 2017-04-01

Journal Articles

• Rapid Progression to Decompensated Cirrhosis, Liver Transplantation, and Death in HIV-Infected Men after Primary HCV Infection.  
  Fierer, D, Dietrich, D, Fiel, M., Hsu, R, et al, Clinical Infectious Diseases
• The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation – The International HIV Controllers Study.  
  Walker, B., Hsu, R and multiple authors, et al, Journal of Antimicrobial Chemotherapy
• Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once a day abacavir/lamivudine/...  
  Ross, L., Hsu, R., Lanier, R., Dejesus, E., Cohen, C., Gathe, J., Hsu, R., et al, AIDS, July; 25(7):665-672
• Effect of Tenofovir Subtraction on HIV Plasma Viremia, CD4 and Resistance in a Patient with Baseline K65R and M184V Mutations.  
  Ross, L., Lanier, R., et al, Antiretroviral Therapy
• Once-Daily Abacavir/lamivudine/zidovudine plus tenofovir for the Treatment of HIV-1 Infection in Antiretroviral-naïve Subjects: a 48 Week Pilot Study.  
  Elion, R., Cohen, C., Dejesus, E., Gathe J., Hsu, R., et al, HIV Clinical Trials, 2006: 7(6): 324-333
• Trends in HIV Disease Management: Protease Inhibitors in Combination Therapy – A Grand Rounds Program.  
  Hsu, R, American Academy of HIV Medicine, Self-Directed HIV Medicine Study Guide, Volume 2
• 48 Week Analysis of Efficacy and Safety of QD Abacavir/Lamivudine/Zidovudine plus Tenofovir.  
  Cohen, C., Elion, R., Dejusus, E., Gathe, J., Hsu, R., et al, ICAAC, vol 45, page 264
• Selection of HIV RT Thymidine Analogue Mutations rather than K65R s the preferred Pathway in Patients with Virologic Failure on QD Trizivir and Tenofovir.  
  Elion, R., Ha, B., Dejusus, E., Cohen, C., Gathe, J., Hsu, R., et al, ICAAC, vol 45, page 271
• Do New Protease Inhibitors Offer Improved Sequencing Options?  
  Hsu, R. and Wainberg, M, JAIDS, Vol. 35, Supplement
• IgG Subclass Deficiency in HIV–1 Infection: A Potentially Unrecognized Secondary Immunodeficiency.  
  Hsu, R, JAIDS
• Sequencing or Success: A Case-Based Educational Program on Drug Resistance in HIV Therapy.  
  Gallant, J., Hsu, R., et al, Johns Hopkins School of Medicine and World Health CME
• Antiretroviral Drug Sequencing: Managing Resistance Across the Continuum of Care.  
  O’Brien, B., Cohan, G., Hsu, R, Discovery International
• The RRE of Human Immunodeficiency Virus Type 1 Contributes to Cell-Type-Specific Viral Tropism.  
  Dayton, E., Konings, D., Lim, S., Hsu, R., et al, Journal of Virology, May 1993, 2871-2878
• Join now to see all

Books/Book Chapters

• American Academy of HIV Medicine, Self-Directed HIV Medicine Study Guide. 
  Hsu, R

Abstracts/Posters

• NRTI Subtraction on HIV Plasma Viremia, CD4-Counts, and Resistance.
  Hsu, R., et al, 3rd International Workshop on HIV Persistence during Therapy, St Maarten, West Indies
• Fosamprenavir with Low-dose Ritonavir Once-Daily in HIV-Infected Subjects.
  Hsu, R. and Acosta, E, 7th Intl. Workshop Pharmacology, Lisbon, Portugal
• COL40263: A Pilot, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of a Once-Daily Regimen of Trizivir/Tenofovir Disoproxil Fumarate in Antiretrovir...
  Elion, R., Dejesus, E., Hsu, R, Abstract 53
• The Combination of Amprenavir with Low Dose Ritonavir in Salvage Regimens Overcomes Clinically Multiple-Drug Resistant Virus.
  Hsu, R. and Bellman, P, The XIII International AIDS Conference, Durban, South Africa
• Role of Fluorine-18-Fluorodeoxyglucose in the Work-up of Febrile AIDS Patients.
  Santiago, JF; Jana, S., Bellman, P., Hsu, R., Et al.,Co, M., Yano, S., Hsu, R., et al, Clinical Positron Imaging, 1999 Nov; 2(6):301-309
• Genomic Heterogeneity of DNA Repair: Role in Aging?
  Hanawalt, P., Gee, P., Hsu, R., Ho, L., and Kane, C, New York Academy of Science Conference Proceedings, 1991, 1-14
• Join now to see all

Lectures

• Complications of NRTI Therapy. 
  Boston, MA, Healthmatters
• Antiviral Activity and Safety of 640385/RTV in HIV Infected Patients (Study HPR10006: A 24-Week Analysis. 
• HIV Clinical Roundtable. 
  New York
• Recent Advances in HIV Therapy. 
  Multiple Locations, 2005-present
• Are the New Protease Inhibitors a New Paradigm in PI-Based Antiretroviral Therapy? 
  Multiple Locations, 2003-2004
• Nucleoside Analogue Resistance and Sequencing. 
  Multiple Locations, 2003-2004
• Incorporating Valcyte into CMV Therapy. 
  Roche Pharmaceutical Headquarters
• Sequencing for Success. 
  Johns Hopkins School of Medicine CME
• Pharmacokinetics of Adherence/Therapeutic Drug Monitoring. 
  Interdisciplinary Theoretical Perspectives on HIV Adherence, Mount Sinai School of Medicine-New York
• HIV/AIDS in Patient Specific Populations. 
  Multiple Locations, 2003-present
• Male Hypogonadism: Prevalence, Diagnoses, and Treatment Strategies. 
• Defining and Treating AIDS-associated Weight Loss and Wasting in the HAART ERA. 
• Updates from Barcelona and ICAAC. 
  Multiple Locations
• Trends in HIV Disease Management: Protease Inhibitors in Combination Therapy. 
• Long-term Complications of Antiretroviral Therapy. 
  Washington D.C, New York-NY, Dallas TX, Boston MA
• Nucleoside & Protease Inhibitor Sequencing. 
  National Advisory Board Speaker, GSK
• Resistance and Sequencing in Antiviral Therapy. 
  New York, Miami, and Houston
• Pharmacokinetic Enhancement of PI Based Treatment with HIV: Five Years Out. 
  Mount Sinai Hospital and Medical Center
• The Use of Amprenavir in Clinical Practice. 
• Pharmacokinetics. 
• Overcomes Clinically Multiple-Drug Resistant Virus. 
  XIII International AIDS Conference, Durban, South Africa
• Strategies in HIV Treatment: An Update, friends indeed. 
  New York, 1998, 2000
• HIV Care Guidelines for the Primary Care Physician. 
  UCLA Medical Center Conference
• HIV-1’s RRE Contributes to Cell-type Specific Viral Tropism. 
  National Institutes of Health
• The Correlation of DNA Repair with Transcriptional Modulation of the Plasminogen Gene Family. 
  Stanford University
• Join now to see all